Los Angeles Capital Management LLC Purchases New Position in AxoGen, Inc. (NASDAQ:AXGN)

Los Angeles Capital Management LLC acquired a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 19,870 shares of the medical equipment provider’s stock, valued at approximately $279,000.

A number of other institutional investors and hedge funds have also bought and sold shares of AXGN. nVerses Capital LLC purchased a new stake in shares of AxoGen in the 3rd quarter worth approximately $56,000. Koss Olinger Consulting LLC bought a new stake in AxoGen during the 2nd quarter valued at $75,000. Lazard Asset Management LLC boosted its position in AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 2,671 shares in the last quarter. Primoris Wealth Advisors LLC purchased a new position in shares of AxoGen in the 3rd quarter valued at $207,000. Finally, Principal Financial Group Inc. bought a new position in shares of AxoGen in the 3rd quarter worth $207,000. 80.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. JMP Securities raised their price objective on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $15.00.

AxoGen Stock Up 1.3 %

AxoGen stock opened at $12.80 on Tuesday. The business has a fifty day moving average price of $13.78 and a 200-day moving average price of $10.43. AxoGen, Inc. has a 1-year low of $5.55 and a 1-year high of $15.90. The stock has a market capitalization of $563.30 million, a price-to-earnings ratio of -40.00 and a beta of 1.13. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.